(Q33223628)

English

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

1 reference

Europe PubMed Central

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

0 references

0 references

biological psychiatry

1 reference

based on heuristic

inferred from title

Birte Yding Glenthøj

4

object named as

Birte Glenthoj

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

object named as

Peter Falkai

1

0 references

Hans-Jürgen Möller

6

object named as

Hans-Jürgen Möller

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

Jeffrey Lieberman

3

object named as

Jeffrey Lieberman

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

Wagner Farid Gattaz

5

object named as

Wagner F Gattaz

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

author name string

Thomas Wobrock

2

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

WFSBP Task Force on Treatment Guidelines for Schizophrenia

7

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

publication date

1 January 2005

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

World Journal of Biological Psychiatry

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

132-191

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

Double-blind, placebo-controlled comparison of the efficacy of sertraline as treatment for a major depressive episode in patients with remitted schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Predictors of acute dystonia in first-episode psychotic patients.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Adjunctive estrogen treatment in women with chronic schizophrenia: a double-blind, randomized, and placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Pharmacogenomic-guided rational therapeutic drug monitoring: conceptual framework and application platforms for atypical antipsychotics

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

What Clinicians Should Know About the QT Interval

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Effects of the atypical antipsychotic risperidone on hostility and aggression in schizophrenia: a meta-analysis of controlled trials

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

The impact of weight gain on quality of life among persons with schizophrenia.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Clonazepam/haloperidol combination therapy in schizophrenia: a double blind study

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Intramuscular preparations of antipsychotics: uses and relevance in clinical practice

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Negative v positive schizophrenia. Definition and validation.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Managing acute exacerbations of schizophrenia: focus on quetiapine

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Motivational interviewing among psychiatric in-patients with substance use disorders

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Suicidality and second generation antipsychotics in schizophrenia patients: a case-controlled retrospective study during a 5-year period

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

The impact of cognitive remediation on psychiatric symptoms of schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Randomized controlled trial of motivational interviewing, cognitive behavior therapy, and family intervention for patients with comorbid schizophrenia and substance use disorders

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Efficacy of mirtazapine add on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Treatment of Obsessive-Compulsive Symptoms in Schizophrenic Patients With Clomipramine

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Catatonia and the neuroleptics: psychobiologic significance of remote and recent findings

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Safety and effectiveness of olanzapine versus conventional antipsychotics in the acute treatment of first-episode schizophrenic inpatients

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

The prediction of criminal and violent recidivism among mentally disordered offenders: a meta-analysis

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Pharmacological management of first-episode schizophrenia and related nonaffective psychoses

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Clinical characteristics of akathisia. A systematic investigation of acute psychiatric inpatient admissions.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Defining treatment refractoriness in schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Causes of the excess mortality of schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Clozapine: efficacy and safety

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Structural evaluation of the prefrontal cortex in schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Substance abuse among patients with treatment-resistant schizophrenia: characteristics and implications for clozapine therapy.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Treatment of the psychotic patient who is violent

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Catatonia. II. Treatment with lorazepam and electroconvulsive therapy.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Treatment of negative symptoms

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride Study Group).

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Pindolol augmentation in aggressive schizophrenic patients: a double-blind crossover randomized study

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Neuroleptics: effects on neuropsychological function in chronic schizophrenic patients

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Gender differences in schizophrenia: hormonal effect or subtypes?

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Combined ECT and neuroleptic therapy in treatment-refractory schizophrenia: prediction of outcome

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Quetiapine. A review of its use in the management of schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Clozapine: its impact on aggressive behavior among patients in a state psychiatric hospital

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Olanzapine in Chinese treatment-resistant patients with schizophrenia: an open-label, prospective trial

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Optimal dosing of atypical antipsychotics in adults: a review of the current evidence

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Adjunctive divalproex and hostility among patients with schizophrenia receiving olanzapine or risperidone

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Family support and substance use outcomes for persons with mental illness and substance use disorders.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Evaluation of treatment-resistant schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Olanzapine response in treatment-refractory schizophrenic patients with a history of substance abuse.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Zotepine in the prevention of recurrence: a randomised, double-blind, placebo-controlled study for chronic schizophrenia.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Dopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

The two-syndrome concept: origins and current status

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Double-blind comparison of alprazolam, diazepam, and placebo for the treatment of negative schizophrenic symptoms.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Sexual dysfunction and antipsychotic treatment

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Different side effect profiles of risperidone and clozapine in 20 outpatients with schizophrenia or schizoaffective disorder: a pilot study

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Side effects of electroconvulsive therapy

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

The varied outcomes of schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Overview: maintenance therapy in psychiatry: I. Schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

A meta-analysis of the efficacy of second-generation antipsychotics

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Dose response and dose equivalence of antipsychotics

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Efficacy and tolerability of quetiapine in patients with schizophrenia switched from other antipsychotics.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Clozapine-related seizures

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Neuroleptic-induced hyperprolactinemia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Conventional antipsychotic medications for schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Electroconvulsive therapy and memory loss: a personal journey

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Intramuscular flunitrazepam versus intramuscular haloperidol in the emergency treatment of aggressive psychotic behavior.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

The effectiveness of olanzapine in treatment-refractory schizophrenia when patients are nonresponsive to or unable to tolerate clozapine.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Psychosocial approaches to dual diagnosis

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Comorbid non-alcohol substance misuse among people with schizophrenia: epidemiological study in central London

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Clozapine plus lamotrigine in treatment-resistant schizophrenia.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Augmenting antipsychotic treatment with lamotrigine or topiramate in patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Risperidone Working Group

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Clinical potential of omega-3 fatty acids in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Clozapine eligibility among state hospital patients

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

ICI 204,636, a novel, atypical antipsychotic: early indication of safety and efficacy in patients with chronic and subchronic schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Significant interaction between clozapine and cocaine in cocaine addicts

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Prognostic scale for chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Convulsive therapy in schizophrenia?

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

An open comparison of clozapine and risperidone in treatment-resistant schizophrenia.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Patterns of current and lifetime substance use in schizophrenia.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Interventions to reduce the stigma associated with severe mental illness: experiences from the open the doors program in Germany.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Clozapine maintenance therapy in schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Neuroleptic reduction of cocaine-induced paranoia but not euphoria?

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Physical and sexual assault history in women with serious mental illness: prevalence, correlates, treatment, and future research directions

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Does risperidone improve verbal working memory in treatment-resistant schizophrenia?

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Alcohol and cannabis use in schizophrenia: effects of clozapine vs. risperidone

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Cost of schizophrenia to UK Society. An incidence-based cost-of-illness model for the first 5 years following diagnosis

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Antipsychotic-related QTc prolongation, torsade de pointes and sudden death

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double-blind trial.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

[Effectiveness of zotepine in therapy-refractory psychoses. An open, multicenter study in eight psychiatric clinics]

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Randomized, controlled, double-blind, multicenter comparison of the cognitive effects of ziprasidone versus olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Somatic treatment of catatonia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

One hundred years of schizophrenia: a meta-analysis of the outcome literature.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Risperidone versus clozapine in the treatment of schizophrenic patients with acute symptoms: a double blind, randomized trial

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Twenty years' follow-up of first psychiatric presentation for schizophrenia: what could have been prevented?

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Acute and long-term treatment of catatonia with risperidone

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Effectiveness of ECT combined with risperidone against aggression in schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Transcranial magnetic stimulation of left temporoparietal cortex and medication-resistant auditory hallucinations.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Medication compliance and comorbid substance abuse in schizophrenia: impact on community survival 4 years after a relapse.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

A trial of low doses of risperidone in the treatment of patients with first-episode schizophrenia, schizophreniform disorder, or schizoaffective disorder

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Olanzapine versus haloperidol in the treatment of patients with chronic schizophrenia: results of the Japan multicenter, double-blind olanzapine trial

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Treatment of late-life schizophrenia with neuroleptics

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Medical comorbidity in schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

The Northwick Park Study of first episodes of schizophrenia. I. Presentation of the illness and problems relating to admission

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Psychopharmacologic treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Switching treatment-resistant patients with schizophrenia or schizoaffective disorder to olanzapine: a one-year open-label study with five-year follow-up

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Citalopram augmentation of antipsychotic treatment in older schizophrenia patients

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Risperidone versus haloperidol for perception of emotion in treatment-resistant schizophrenia: preliminary findings

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Myocarditis and cardiomyopathy associated with clozapine

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Mechanisms of action of atypical antipsychotic drugs: a critical analysis

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Dose response and atypical antipsychotics in schizophrenia.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Prolactin levels and adverse events in patients treated with risperidone.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Outpatient treatment of patients with substance abuse and coexisting psychiatric disorders.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Extrapyramidal signs and clinical symptoms in first-episode schizophrenia: response to low-dose risperidone.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Rapid death during cocaine abuse: a variant of the neuroleptic malignant syndrome?

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Sulpiride augmentation of olanzapine in the management of treatment-resistant chronic schizophrenia: evidence for improvement of mood symptomatology

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Substance use disorder and the early course of illness in schizophrenia and affective psychosis.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Costs of schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Combined electroconvulsive and neuroleptic therapy in schizophrenia refractory to neuroleptics.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Use of atypical antipsychotics during pregnancy and the risk of neural tube defects in infants

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Elevated clozapine plasma level with lamotrigine

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Effect of neuroleptic treatment on depressive symptoms in acute schizophrenic episodes

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Placebo-controlled trial of lamotrigine added to conventional and atypical antipsychotics in schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Toward a rational pharmacotherapy of comorbid substance abuse in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Childhood-onset schizophrenia. A double-blind clozapine-haloperidol comparison

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Combined electroconvulsive-clozapine therapy.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Myocarditis and cardiomyopathy associated with clozapine use in the United States

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

"Catatonic dilemma". Therapy with lorazepam and clozapine

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

A double-blind study of adjunctive sertraline in haloperidol-stabilized patients with chronic schizophrenia.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Discovering the neural basis of human social anxiety: a diagnostic and therapeutic imperative

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Combined use of risperidone and olanzapine in the treatment of patients with resistant schizophrenia: a preliminary case series report

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Sex differences in schizophrenia, a review of the literature

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Flupenthixol treatment for cocaine abusers with schizophrenia: a pilot study

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Olanzapine for schizophrenia refractory to typical and atypical antipsychotics: an open-label, prospective trial

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Olanzapine treatment for patients with schizophrenia and substance abuse

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Conjugated estrogens as adjuvant therapy in the treatment of acute schizophrenia: a double-blind study.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Risperidone in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

The Mount Sinai conference on the pharmacotherapy of schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Physical health monitoring of patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Subtype progression and pathophysiologic deterioration in early schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Early detection and intervention with schizophrenia: rationale

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Suicidality in schizophrenia: a review of the evidence for risk factors and treatment options

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT).

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Improvement of cognitive function in schizophrenic patients receiving clozapine or zotepine: results from a double-blind study.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Review: treatment of schizophrenia. State of the art.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Definition, psychopharmacological basis and clinical evaluation of novel/atypical neuroleptics: methodological issues and clinical consequences

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

State of the art of drug treatment of schizophrenia and the future position of the novel/atypical antipsychotics

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

The Kraepelinian dichotomy: preliminary results of a 15-year follow-up study on functional psychoses: focus on negative symptoms

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Management of the negative symptoms of schizophrenia: new treatment options

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Novel antipsychotics in the long-term treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Non-neuroleptic approaches to treating negative symptoms in schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Antidepressive effects of traditional and second generation antipsychotics: a review of the clinical data

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re-evaluation of the North American risperidone study

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Zotepine versus placebo in the treatment of schizophrenic patients with stable primary negative symptoms: a randomized double-blind multicenter trial

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Prevalence of substance abuse in schizophrenia: demographic and clinical correlates.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Disulfiram treatment for alcoholism in severe mental illness

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Six-month outcomes for patients who switched to olanzapine treatment

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Pharmacotherapy for schizophrenia and co-occurring substance use disorders

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

A double-blind study of adjunctive carbamazepine versus placebo on excited states of schizophrenic and schizoaffective disorders.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Tardive dyskinesia in psychiatric patients with substance use disorders.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Determining the optimal dose of haloperidol in first-episode psychosis

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Depressive symptoms at baseline predict fewer negative symptoms at follow-up in patients with first-episode schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Short-term inpatient pharmacotherapy of schizophrenia.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Neuroleptic malignant syndrome: a review

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Synergism of lorazepam and electroconvulsive therapy in the treatment of catatonia.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

A comparison of smoking behaviours between patients treated with clozapine and depot neuroleptics

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Concomitant clozapine reduces smoking in patients treated with risperidone

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Subjective memory complaints: a review of patient self-assessment of memory after electroconvulsive therapy

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Atypical antipsychotics: pharmacokinetics, therapeutic drug monitoring and pharmacological interactions

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Olanzapine and sulpiride: a preliminary study of combination/augmentation in patients with treatment-resistant schizophrenia.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

An open study of fluvoxamine augmentation of neuroleptics in schizophrenia with obsessive and compulsive symptoms.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

A double-blind placebo-controlled case study of the use of donepezil to improve cognition in a schizoaffective disorder patient: functional MRI correlates

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Olanzapine for the treatment of chronic refractory schizophrenia: a 12-month follow-up naturalistic study

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

High frequency repetitive transcranial magnetic stimulation (rTMS) of the dorsolateral prefrontal cortex in schizophrenic patients.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Acute dystonia induced by neuroleptic drugs

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Lamotrigine--clozapine combination in refractory schizophrenia: three cases

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Olanzapine versus haloperidol treatment in first-episode psychosis

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Relationship of clinical symptoms and substance use in schizophrenia patients on conventional versus atypical antipsychotics

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Reboxetine add on therapy to haloperidol in the treatment of schizophrenia: a preliminary double-blind randomized placebo-controlled study

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind study

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Chemical brain anatomy in schizophrenia.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Clinical guidelines: developing guidelines

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Clozapine, chlorpromazine, and placebo in newly hospitalized, acutely schizophrenic patients: a controlled, double-blind comparison

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Augmentation with fluvoxamine but not maprotiline improves negative symptoms in treated schizophrenia: evidence for a specific serotonergic effect from a double-blind study

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

The onset and time course of response of negative symptoms to add-on fluvoxamine treatment

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Selective serotonin reuptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Pharmacological treatment of substance-abusing schizophrenic patients

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Antidepressant for substance-abusing schizophrenic patients: a minireview

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Depression in schizophrenia: perspective in the era of "Atypical" antipsychotic agents

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Suicide and schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Prevalence of alcohol and drug abuse in schizophrenic inpatients

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Flupenthixol in relapse prevention in schizophrenics with comorbid alcoholism: results from an open clinical study

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Metabolic drug interactions with new psychotropic agents.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

An open trial of risperidone augmentation of partial response to clozapine.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Safety of quetiapine during pregnancy

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Quetiapine and pregnancy

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

D-serine added to antipsychotics for the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Benzodiazepines and the psychopathology of catatonia.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Response of catatonia to risperidone: two case reports.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Symptom response and side-effects of olanzapine and risperidone in young adults with recent onset schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

A controlled dose comparison of haloperidol in newly admitted schizophrenic patients

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Citalopram, a selective serotonin reuptake inhibitor, in the treatment of aggression in schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Does cognitive function improve with quetiapine in comparison to haloperidol?

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

High-dose treatment with haloperidol: the effect of dose reduction.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Risperidone versus clozapine in treatment-resistant schizophrenia: a randomized pilot study.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Practitioner review: electroconvulsive therapy in adolescents

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Randomized, placebo-controlled pilot study of divalproex sodium in the treatment of acute exacerbations of chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

GABA and Schizophrenia: A Review of Basic Science and Clinical Studies

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Quetiapine in the successful treatment of schizophrenia with comorbid alcohol and drug dependence: a case report

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

The effects of second-generation antipsychotics on cognitive functioning and psychosocial outcome in schizophrenia.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology -- a double-blind controlled study comparing a selective D2-like antagonist to a mixed D1-/D2-like antagonist. The Amisulpride Study Group

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

[Psychotherapy of positive symptoms in the treatment of patients with schizophrenia psychosis]

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Flupenthixol decanoate and relapse prevention in alcoholics: results from a placebo-controlled study

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Pharmacotherapy of schizophrenia patients with comorbid substance abuse.

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Benzodiazepines in the treatment of schizophrenia: a review and reappraisal

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Consistency of atypical antipsychotic superiority to placebo in recent clinical trials

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Propranolol as an adjunct to the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Relationship of psychotic symptom clusters in schizophrenia to neuroleptic treatment and growth hormone response to apomorphine

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Risperidone versus haloperidol in the treatment of acute exacerbations of chronic inpatients with schizophrenia: a randomized double-blind study

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Effects of clozapine on substance use in patients with schizophrenia and schizoaffective disorder: a retrospective survey

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

The effect of mirtazapine augmentation of clozapine in the treatment of negative symptoms of schizophrenia: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Establishing the onset of psychotic illness

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Combined treatment of schizophrenic psychoses with haloperidol and valproate

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

A randomized, controlled comparison of the efficacy and tolerability of low and high doses of haloperidol in the treatment of first-episode psychosis

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

What are the functional consequences of neurocognitive deficits in schizophrenia?

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Half a century of ECT use in young people

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Successful treatment with flupenthixol decanoate of a patient with both schizophrenia and alcoholism

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Sex and Schizophrenia: Effects of Diagnostic Stringency, and Associations with Premorbid Variables

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Risperidone and clozapine combination for the treatment of refractory schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Fluoxetine as an Adjunct to Conventional Antipsychotic Treatment of Schizophrenia Patients with Residual Symptoms

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

The Influence of Age and Sex on the Onset and Early Course of Schizophrenia

1 reference

https://api.crossref.org/works/10.1080%2F15622970510030090

21 January 2018

Identifiers

10.1080/15622970510030090

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33223628&oldid=1977237990"